Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | BLM | P54132 | 4/20 | 0.47 |
| ▸ | RECQL | P46063 | 3/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16166137 | 0.91 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL18902663 | 0.86 | MEN1 (0.51) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL16166500 | 0.86 | MEN1 (0.62) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL7487588 | 0.86 | MEN1 (0.55) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL7035542 | 0.83 | MEN1 (0.52) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL18001904 | 0.82 | MAPT (0.48) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL8778013 | 0.81 | MEN1 (0.47) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL6468593 | 0.79 | MEN1 (0.48) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL574432 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL7487255 | 0.78 | MAPT (0.63) | ALDH1A1MEN1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984070-B1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND PHARMA LTD (IN) | 2018-01-17 | — | — | EP | claimed |
| US-9862681-B2 | N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives | MANKIND RESEARCH CENTRE (IN) | 2018-01-09 | — | — | US | claimed |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | MANKIND PHARMA LTD (IN) | 2016-02-18 | — | — | US | claimed |
| EP-2984070-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | Mankind Research Centre (IN) | 2016-02-17 | — | — | EP | claimed |
| CN-105102429-A | N-haloalkylindoline intermediates, process and use in preparation of silodosin and derivatives thereof | MANKIND RES CT | 2015-11-25 | — | — | CN | claimed |
| WO-2014167507-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND RESEARCH CENTRE (IN) | 2014-10-16 | — | — | WO | claimed |
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2019-03-26 | — | — | US | disclosed |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2018-04-26 | — | — | US | disclosed |
| EP-2984070-B1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND PHARMA LTD (IN) | 2018-01-17 | — | — | EP | disclosed |
| US-9862681-B2 | N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives | MANKIND RESEARCH CENTRE (IN) | 2018-01-09 | — | — | US | disclosed |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | MANKIND PHARMA LTD (IN) | 2016-02-18 | — | — | US | disclosed |
| EP-2984070-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | Mankind Research Centre (IN) | 2016-02-17 | — | — | EP | disclosed |
| CN-105102429-A | N-haloalkylindoline intermediates, process and use in preparation of silodosin and derivatives thereof | MANKIND RES CT | 2015-11-25 | — | — | CN | disclosed |
| WO-2014167507-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND RESEARCH CENTRE (IN) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | ADRA1D, ADRB1, ADRA1A | ALDH1A1 116/4885MEN1 2109/4885KMT2A 3333/4885 |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | ADRA1D, ADRA1A, ADRB1 | ALDH1A1 123/4885MEN1 2015/4885KMT2A 3543/4885 |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | ADRA1D, ADRA1A, ADRB1 | ALDH1A1 103/4885MEN1 1463/4885KMT2A 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.